Navigation Links
Pfizer to Acquire FoldRx Pharmaceuticals
Date:9/1/2010

t FoldRx's product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties.  Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx's technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)...  Lightbeam Health Solutions announced today an agreement ... ACO) to deploy the Lightbeam population health platform ... while reducing costs. Photo - ... Care Organization is the ACO operating entity of ... is to be the premier integrated health care ...
(Date:9/17/2014)... Fla. , Sept. 17, 2014   myMatrixx, a pharmacy ... today that Business Insurance magazine has awarded ... distinction for the third year in a row. ... effort of Business Insurance  and the Best Companies ... is open to all publicly or privately-held insurance industry ...
(Date:9/17/2014)... Sept. 17, 2014  NuView Life Sciences, Inc. ... and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. ... genomic-based diagnostic biomarker to detect cancers of the ... other future diagnostic-imaging applications. NuView retains all rights ... and in-vitro urine screen applications. Under ...
Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5
... 6 Reportlinker.com announces that a new ... catalogue. , Reportlinker Adds Gilead ... http://www.reportlinker.com/p0151769/Reportlinker-Adds-Gilead-Sciences-Inc-PharmaVitae-Profile.html , Introduction , This ... for Gilead in the prescription pharmaceutical sector. ...
... Oct. 6 Centocor Ortho Biotech Inc. and Schering-Plough ... European Commission has approved SIMPONI(TM) (golimumab) as a once-monthly, ... arthritis (RA), active and progressive psoriatic arthritis (PsA) and ... the European Union, SIMPONI is approved as a 50 ...
Cached Medicine Technology:Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile 2Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile 3Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 2SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 3SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 5SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 6SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 7SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 8SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 9SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 10
(Date:9/17/2014)... North Central Surgical Center is proud to announce ... top-notch services. The hospital was the recipient for several ... , Hospital-wide, North Central was the recipient of the ... award for two years in a row (2013-2014). They ... nation for Patient Safety in 2014 and ranked among ...
(Date:9/17/2014)... blood test that measures DNA from a prostate cancer ... the state of a man,s disease, a new study ... could reveal when treatment for advanced prostate cancer ... researchers suggested. "Our study showed that a steroid ... often initially very effective started to activate harmful mutations ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... Why are Asian Americans at higher risk of ... to develop the disease at lower body weights? One ... from traditional high-fiber, low-fat Asian diets to current westernized ... Asian heritage, says George King, M.D., Senior Vice President ... the senior author of the study. , A Joslin ...
(Date:9/17/2014)... London, UK (PRWEB) September 17, 2014 ... of the total medical technology market, focusing on molecular ... cancer, chronic diseases, and genetic testing. The IVD market ... billion by the end of 2017. The major drivers ... testing; need for speed, which is evidenced by the ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... explain the increased cases , FRIDAY, Nov. 6 (HealthDay News) ... people at higher risk of getting a type of thyroid ... related to cancer, but researchers suspect that the toxic compounds ... also unsure of why thyroid cancer rates are rising around ...
... a sneeze, people worry more about flu, heart attacks, accidents and ... may sound hard to believe, but just one sneeze is enough ... of dying from a heart attack at an early age, dying ... new research shows. , Of greater concern, however, was that people ...
... Nov. 6 HeartWare International, Inc. (Nasdaq: ... provider of less invasive, miniaturized circulatory support technologies revolutionizing ... it is scheduled to make presentations at two upcoming ... be made at the Third Annual Canaccord Adams Cardiovascular ...
... ... Award. , ... LA (PRWEB) November 6, 2009 -- Gilsbar, a national leader in health benefit ... was recently honored with Platinum-Level recognition for the American Heart Association Start! Fit-Friendly Companies ...
... ... and the recently released World Alzheimer Report declares that more than 35 million people ... innovator with 16 independent living and assisted living, and Alzheimer,s/memory care communities in Wisconsin ... of Alzheimer,s disease. , ...
... Tobacco-Free Kids, American Cancer Society, American Cancer Society Cancer ... American Legacy Foundation , WASHINGTON, Nov. 5 ... judge in Kentucky today rejected a motion by tobacco ... giving the U.S. Food and Drug Administration (FDA) the ...
Cached Medicine News:Health News:Thyroid Cancer Higher in Volcanic Areas 2Health News:Health Fears Are Nothing to Sneeze At 2Health News:Health Fears Are Nothing to Sneeze At 3Health News:HeartWare to Present at Upcoming Investment Conferences in November 2Health News:Gilsbar is Sole Louisiana Company to Win National Award from the American Heart Association 2Health News:Top 10 Ways to Prevent or Delay Alzheimer's 2Health News:Federal Judge Rejects Tobacco Companies' Effort to Block Key Provisions of New Tobacco Regulation Law 2
... Single use curved circular ... and titanium staples., ,The ... stapler is used throughout the ... of end-to-end, end-to-side and side-to-side ...
The Auto Suture™ EEA™ reusable stainless steel sizer set has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
... is synthesized in the parafollicular C-cells of ... secretory granules. The major action of calcitonin ... inhibiting osteoclast activity, resulting in decreased mobilization ... is most evident in conditions associated with ...
... The pHEM-ALERT® test provides a method for ... The pHEM-ALERT test is comprised of a plastic ... color chart and a package insert. The plastic ... flat key. pHEM-ALERT is indicated for measuring vaginal ...
Medicine Products: